

## Dr. George Poste

Dr. Poste is Chief Scientist, Complex Adaptive Systems Initiative (CASI) at Arizona State University. This program links expertise across the university in research on synthetic biology, ubiquitous sensing and healthcare informatics for personalized medicine.

He also founded the Biodesign Institute at ASU ([www.biodesign.asu.edu/](http://www.biodesign.asu.edu/)). Dr. Poste achieved research funding of \$225 million and recruited over 60 faculty, including three members of the National Academies of Science and Engineering.



He also serves as Chief Executive of a consulting company, Health Technology Networks, which specializes in the application of genomic technologies and computing in healthcare. Dr. Poste is Chairman of Orchid Biosciences, the leading company in DNA forensic analysis, and serves on the Board of Directors of Monsanto, Exelixis and Caris Dx. From 1992 to 1999 he was Chief Science and Technology Officer and President, R&D of SmithKline Beecham (SB). During his tenure at SB he was associated with the successful registration of 31 drug, vaccine and diagnostic products. In 2004 he was named as 'R&D Scientist of the Year' by R&D Magazine and in 2006 he received the Einstein award from the Global Business Leadership Council.

Dr. Poste has published over 350 research papers and edited 14 books on pharmaceutical technologies and oncology. He has received honorary degrees in science, law and medicine for his research contributions and was honored in 1999 by HM Queen Elizabeth II as a Commander of the British Empire for his contributions to international security.

He is a Fellow of the Royal Society, the Royal College of Pathologists and the UK Academy of Medicine, a Distinguished Fellow at the Hoover Institution, Stanford University and a member of the Council for Foreign Relations. Dr. Poste is a member of the Defense Science Board and Health Board of the US Department of Defense (DoD) and the US Institute of Medicine Board on Global Health. On top of everything else, he is Chair of the DOD Task Force on Bioterrorism and the newly launched DOD Task Force on Synthetic Biology.